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Abstract
Purpose This study investigated the relationship between the vitamin D [25(OH)D] level in individual follicles and oocyte
developmental competence.
Methods A prospective cohort study in a private infertility center. Infertile women (N = 198) scheduled for intracytoplasmic
sperm injection (ICSI) and a single embryo transfer (SET) provided serum samples and 322 follicular fluid (FF) specimens, each
from a single follicle on the day of oocyte retrieval.
Results FFs corresponding to successfully fertilized oocytes (following ICSI) contained significantly lower 25(OH)D level
compared with those that were not fertilized (28.4 vs. 34.0 ng/ml, P = 0.001). Top quality embryos on the third day after
fertilization, when compared to other available embryos, developed from oocytes collected from follicles containing
significantly lower 25(OH)D levels (24.56 vs. 29.59 ng/ml, P = 0.007). Positive hCG, clinical pregnancy, and live birth
rates were achieved from embryos derived from oocytes that grew in FF with significantly lower 25(OH)D levels than in
follicles not associated with subsequent pregnancy. The concentration of 25(OH)D in FF in women with negative hCG was
32.23 ± 20.21 ng/ml, positive hCG 23.62 ± 6.09 ng/ml, clinical pregnancy 23.13 ± 6.09 ng/ml, and live birth 23.45 ±
6.11 ng/ml (P < 0.001). Women with serum 25(OH)D < 20 ng/ml had not only a higher fertilization rate (71 vs. 61.6%,
P = 0.026) and a higher clinical pregnancy rate (48.2 vs. 25%, P = 0.001), but also higher miscarriage rate (14.5 vs. 3.8%,
P = 0.013) compared with those with levels ≥ 20 ng/ml.
Conclusion This study reveals that the level of 25(OH)D in FF correlates negatively with the oocytes’ ability to undergo
fertilization and subsequent preimplantation embryo development. Oocytes matured in FF with low 25(OH)D concentration
are more likely to produce top quality embryos and are associated with higher pregnancy and delivery rates. On the other hand,
low serum vitamin D concentration is associated with higher miscarriage rates.
Keywords Oocyte quality . Vitamin D [25(OH)D] . Follicular fluid . ICSI (intracytoplasmic sperm injection) . Single embryo
transfer (SET)
Introduction
Traditionally, recognized actions of vitaminD include calcium
and phosphorus homeostasis, as well as the support of bone
mineralization, while its deficiency leads to an increased risk
of osteoporosis, bone fractures, and muscle weakness [1].
However, there is growing evidence that 25-hydroxyvitamin
D [25(OH)D] exerts many other important actions, especially
on human reproductive functions [2]. Vitamin D can contrib-
ute to the restoration of the menstrual cycle and endometrial
proliferation [3, 4], promote the development of follicles [5],
ameliorate primary dysmenorrhea [6], and reduce the occur-
rence of uterine fibroids [7]. Vitamin D receptors (VDR) have
been identified in the female reproductive tissues including
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human ovarian, endometrial and fallopian tube epithelial cells,
placenta, and decidual cells [8]. Vitamin D via its receptor can
modulate ovarian steroidogenesis [9]. Expression of VDR is
increased during pregnancy. Additionally, data from clinical
reports suggest that lower vitamin D level is associated with
gestational diabetes and preeclampsia [10, 11].
However, the relationship of vitamin D levels with IVF
outcomes remains controversial. Although Polyzos et al.
[12] reported that women with deficient serum vitamin D
had a lower clinical pregnancy rate compared to women with
normal levels of vitamin D, other studies led to opposite con-
clusions [13–18]. Because of these conflicting reports, and
given that vitamin D deficiency is not correlated with ovarian
stimulation characteristics or with markers of embryo quality
[15, 19], it has been postulated that vitamin D deficiency may
negatively affect pregnancy rates in IVF with an effect medi-
ated through the endometrium [12, 15, 20]. In both the epi-
thelial and stromal cells of the endometrium, vitamin D in-
duces and upregulates the transcription of HOXA 10, a gene
essential for implantationwith increased expression during the
window of implantation [21, 22]. Conversely, when a transfer
of synchronous euploid blastocyst is performed, the vitamin D
status does not impact the outcomes [14].
To date, published studies on vitamin D and assisted repro-
duction technologies (ART) have reported outcomes related to
clinical pregnancy rates or live birth rates. However, these
studies were not designed to evaluate the direct relationship
of local-intrafollicular vitamin D levels with the ability of the
individual oocyte to undergo fertilization and subsequent em-
bryo development [13–15, 18, 23, 24]. The present prospec-
tive study has been designed to investigate the possible rela-
tionship between the vitamin D level in individual follicles
and the oocyte developmental competence. Therefore, the first
follicle from each ovary was aspirated separately, and follicu-
lar fluid (FF) from that follicle was matched to its oocyte.
Subsequently, we have followed the outcome of each oocyte,
evaluating its ability to undergo fertilization, subsequent pre-
implantation embryonic development, implantation, and ulti-
mately pregnancy.
Materials and methods
Patient population and study design
The study protocol was approved by the Ethics
Committee of Pomeranian Medical University (PMU),
Szczecin, Poland (ethical authorization number: KB-
0012/90/10). All patients signed an informed consent ap-
proved by the PMU Ethics Committee. All methods were
performed in accordance with the relevant guidelines and
regulations of European Society of Human Reproduction
and Embryology (ESHRE), The American Society for
Reproductive Medicine (ASRM) and The Polish Society
of Reproductive Medicine and Embryology (PSRME).
Subjects
All infertile women without hydrosalpinx between the
ages of 18 and 38 years were considered eligible. They
were scheduled for controlled ovarian hyperstimulation
(COH) in either agonist or antagonist protocol,
intracytoplasmic sperm injection (ICSI) and a single em-
bryo transfer (SET) within a period of 21 months
(February 2014–October 2015). The primary aim of the
study was to evaluate a possible relationship between the
vitamin D level in FF and the matched oocyte’s ability to
generate an embryo resulting in pregnancy and ultimately
a delivery after ICSI. None of the patients in the study
received vitamin D supplementation before COH. To
avoid the potential negative impact of sperm quality on
the ability to fertilize an egg or embryo development,
couples with moderate or severe male factor were exclud-
ed. The exclusion criteria were as follows: (1) moderate
(concentrations 5 million–10 million sperms/ml) and se-
vere (concentrations less than 5 million sperms/ml) male
factor, (2) poor ovarian response to gonadotropin stimu-
lation defined as ≤ 3 retrieved oocytes, and (3) inability to
retrieve an oocyte from the first aspirated follicle of both
ovaries.
25(OH)D measurement
25-Hydroxyvitamin D is the primary circulating form of vita-
min D and remains stable throughout the menstrual cycle [25].
Due to its stability, serum 25(OH)D concentration is viewed
as the best indicator of vitamin D status [26, 27]. Li-heparin
serum samples and follicular fluid samples from all patients
were obtained on the day of oocyte retrieval and kept frozen at
− 80 °C until the measurement was taken. 25(OH)D level was
measured using the chemiluminescent immunoassay (CLIA)
LIAISON® 25 OH Vitamin D TOTAL Assay (REF 310600),
DiaSorin Inc., Stillwater, MN, USA. The limit of quantitation
of the assay was ≤ 4.0 ng/ml. Precision, as reported in the
assay instructions for use, was determined by testing six serum
samples, and two levels of LIAISON 25 OH Vitamin D
TOTAL controls over 20 days according to the CLSI protocol
EP05-A2 [26]; the total precision coefficients of variation
were in the range of 12.6–10.8% (7.9–112.1 ng/ml) for serum
and 9.7–9.5% (18.0–61.8 ng/ml) for kit controls. Vitamin D
deficiencywas defined by the Institute ofMedicine (IOM) and
the Endocrine Society Clinical Practice Guidelines [28, 29] as
serum 25(OH)D level < 20 ng/ml. Follicular fluid vitamin D
norm remains unknown.
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Follicular fluid collection
FF samples were collected according to the strict procedure
described in detail elsewhere [30]. To collect clear follicular
fluid and to avoid multiple vaginal punctures and the numer-
ous flushing of the needle with culture medium after every
follicular puncture, as well as to minimize the risk of vaginal
bleeding, we decided to include in the study FF only from the
first nearest (available) aspirated (lead) follicle of each ovary.
Consequently, vitamin D levels were representative for the
lead follicle only, and not for the entire cohort of follicles from
any given patient. Each ovarian follicle was aspirated inde-
pendently and collected in a separate test tube to identify the
matched single cumulus–oocyte–complex (COC). This ap-
proach was chosen to avoid cross-contamination from the
flush medium or the FF of other follicles. Test tubes with more
than one COC were excluded from the study. In each case
collected, FF was checked afterward for red blood cells.
Fluids with the red blood cells were disqualified. FF samples
with matched mature metaphase II (MII) oocytes were centri-
fuged at 10,000×g for 10 min, and the supernatants were
aliquoted and stored at − 80 °C.
Intracytoplasmic sperm injection
This study included only women undergoing ICSI to allow a
precise cumulus–oocyte–complex evaluation, especially with
regard to its maturity/degradation prior to fertilization.
Furthermore, during conventional IVF insemination, there
are significant events that take place, such as sperm penetra-
tion through layers of supporting granulosa cells, sperm mem-
brane breaching, and fusion; thus, IVF requires competent
oocyte and capable spermatozoa. All these events are
circumvented by the ICSI procedure. While ICSI may affect
the integrity of an oocyte, the literature supports the concept
that oocyte ICSI degeneration is operator-independent [31].
During ICSI micromanipulation, holding pipettes (K-
HPIP-3335, Cook, USA) and injection pipettes (K-MPIP-
1035, Cook, USA) were used. Injected oocytes were placed
in Sydney IVF Cleavage Medium G20720, K-SICM-20
(Cook Medical Inc., Bloomington, IN, USA) immediately af-
ter the procedure. This medium was used during the first 72 h
of the culture, and for the following 48 h, Sydney IVF
Blastocyst Medium G20722, K-SIBM-20 (Cook Medical
Inc., Bloomington, IN, USA) was used. Post-fertilization em-
bryo culture was carried out in a single microdroplet (0.03 ml)
of the medium on a Petri dish under a layer of mineral oil.
Each fertilized oocyte was cultured in an individual drop.
Embryo assessment
Embryos underwent regular embryo assessment as described by
the 2011 Istanbul consensus [32]. A top quality embryo (TQE)
on the second day of the culture was defined as an embryo with
four symmetrical, non-fragmented blastomeres, whereas a TQE
on the third day of the culture was defined as an embryo with
eight symmetrical, non-fragmented blastomeres. On the fifth day
of the culture, at the blastocyst stage, three criteria were taken
into consideration: the development of inner cell mass (ICM),
the appearance of trophectoderm (TE), and expansion of the
blastocyst cavity. The TQE on day 5 was considered to have
fully expanded (grade 4) through to a hatched (grade 5) blasto-
cyst with a high-quality ICM (grade 1) and TE (grade 1) [32].
Embryo transfer policy
In each case, a single embryo transfer was performed.
Embryos were selected for fresh transfer on day 3 if there were
one or two TQE in the whole group of embryos. In the pres-
ence of more than two TQE available in a cohort of develop-
ing embryos, day 5 ETwas performed.
Outcome measures
The primary aim of this study was to determine whether local-
intrafollicular vitamin D correlates with ICSI/SET results. In
particular, in order to examine development competence of
oocyte, the following parameters were taken into consideration:
& Ability of the oocyte to form two pronuclei (2PN) zygote
after ICSI
& Stages of embryogenesis based on accurate cell division
and cellular differentiation of the embryo within fixed
times
& Positive hCG rate after SET, measured 3 weeks after oo-
cyte retrieval
& Clinical pregnancy rate after SET defined as the presence
of an intrauterine sac with an embryonic pole demonstrat-
ing cardiac activity at 7 weeks of gestation
& Live birth rate after SET
We also investigated the association between vitamin D
serum level and IVF clinical outcomes, such as chemical preg-
nancy rate, clinical pregnancy rate, and live birth rate.
Statistical methods
To facilitate sample size, we decided to apply a study from
Ozkan et al. [15] in which the difference in FF 25(OH)D
between the women who achieved pregnancy and those of
women that did not become pregnant were significantly dif-
ferent: 34.42 ± 15.58 vs. 25.62 ± 10.53, P = 0.013, respective-
ly. Therefore, for two independent study groups using clinical
pregnancy as a primary outcome using a significance level of
0.05 and a 95% confidence interval (CI), total sample size of
106 has a 90% power to detect the wanted difference. In our
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study, we included a group of 106 patients undergoing single
embryo transfer (SET). Continuous variables are presented as
means ± standard deviations, and categorical variables are
presented as percentages. The analysis was performed with
the use of an independent t test for continuous variables and
with the use of the χ2 test for categorical variables. Stepwise
logistic regression was applied to identify independent vari-
ables associated with miscarriage and live birth rates. The
significance level of each candidate predictive variable was
set at P < 0.05 to enter the model. After selection of the can-
didate predictive factors, the final model included those prog-
nostic factors with statistical significance according to the
Wald statistic test at a threshold of P < 0.05. Receiver operat-
ing characteristics (ROC) curves were also fitted to obtain
cutoff values for vitamin D levels using the area under the
curve (AUC). Analyses were performed using Statistica 10
software (StatSoft Inc., USA).
Results
Study group characteristics
Out of 325 patients eligible for the study between February
2014 and October 2015, 198 patients were included in this
study with a mean (± SD) age of 34.3 ± 3.9 and BMI of
23.15 ± 3.7 kg/m2 (Table 1). The indication for ICSI was pri-
marily an idiopathic infertility factor. Two thirds of the spec-
imens were obtained from patients undergoing their first
intracytoplasmic sperm injection/single embryo transfer
(ICSI/SET). Almost half of the women underwent COH in
GnRH agonist protocol. In 124 patients, FF was obtained from
both ovaries, whereas in 74 patients, FF was obtained from
one ovary. In 106 patients, transferred embryos developed
from oocytes with matched FF (all data are in Table 1).
Follicular fluid vitamin D level and embryological data
Out of total collected 322 FF samples, 74 were obtained from
one ovary of a patient and 248 from both ovaries of 124 patients.
We found a positive correlation between serum and follicular
fluid 25(OH)D levels (r = 0.721, P < 0.001). The intrafollicular
concentrations of 25(OH)D in the FF from the same patient
varied and correlated with oocyte fate after ICSI. Mean diameter
of aspirated follicle was 19.9 ± 1.8 mm and mean volume of
aspirated follicle fluid 3.7 ± 1.9 ml (Table 1). Key stages of em-
bryo development are presented in a flowchart in Fig. 1. Vitamin
D levels were significantly lower in FF matched to oocytes that
were successfully fertilized after ICSI compared to those that
were not fertilized (28.4 ± 13.2 vs. 34.0 ± 11.8 ng/ml, P =
0.001) (Fig. 2). Furthermore, top quality (TQ) embryos on the
second and third day after ICSI were produced from oocytes
obtained from follicles with significantly lower vitamin D levels
Table 1 Characteristics of patients and ovarian stimulation
Patients characteristics
Number of patients 198
Age [years], mean (SD) 34.3 (3.9)
BMI [kg/m2], mean (SD) 23.15 (3.7)
Caucasian ethnicity, n (%) 198 (100)
Duration of infertility [years], mean (SD) 3.4 (1.5)
Type of infertility, n (%)a
Primary infertility 162 (81.8)
Mild male factor 20 (10.1)
Idiopathic 123 (62.1)
Ovulatory disorders 27 (13.6)
Tubal factor 18 (9)
Endometriosis 24 (12.1)
Previous IVF/ICSI attempts, n (%)
0 148 (74.7)
≥ 1 50 (25.3)
Stimulation protocol characteristics
Basal AMH [ng/ml], mean SD 2.74 (1.75)
Basal FSH [mIU/ml], mean SD 7.51 (4.12)
Type of GnRH analog
Antagonist, n (%) 107 (54)
Agonist, n (%) 91 (46)
Gonadotrophins [IU], mean (SD) 2177.6 (893.8)
Estradiol on the day of hCG [pg/ml],
mean (SD)
2392.2 (1357.8)
Progesterone on the day of hCG [ng/ml],
mean (SD)
0.918 (0.4)
Follicular fluid samples characteristics
TVS diameter of aspirated follicle [mm], mean (SD) 19.9 (1.8)
Volume of aspirated follicle fluid [ml], mean (SD) 3.7 (1.9)
Number of identified MII oocytes, n 322
Patients with FF samples from both ovaries, n 124
Patients with FF sample only from one ovary, n 74
Vitamin D3 level in follicular fluid [ng/ml],
mean (SD)
29.6 (13.1)
Embryological outcome of the oocytes
with matched FF
Fertilization rate (%), mean (SD) 78.3 (41)
Percentage of TQE (%), mean (SD) 16.7 (37)
Number of SET with an embryo developed
from FF matched oocyteb, n
106
SET of TQEc, n 54
Embryo cryopreservationd, n 60
BMI body mass index, hCG human chorionic gonadotropin, TQE top
quality embryo, TVS transvaginal ultrasound, SET single embryo transfer
a The sum is greater than the total number of patients (198) since some
couples met more than one indication for infertility treatment
b Among 198 patients 106 had SETof embryo developed from the oocyte
with matched follicular fluid
c n = 54 cases transferred embryo was scored as TQE
d In 60 cases oocyte with matched follicular fluid produced an embryo
suitable for cryopreservation
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325 patients eligible for the study
127 patients excluded:
absence of a single recognized COC in the first follicle
immature oocyte in identified COC from both ovaries
poor ovarian response ( 3 retrieved oocytes)
male factor (semen quality on the day of!oocyte retrieval)
198 patients with at least one sample of follicular fluid with a single MII oocyte obtained
322 matched MII oocytes used for ICSI 
252 2PN zygotes on Day 1a
70 oocytes not fertilized  
103 TQ Day 2 embryos 149 non-TQ Day 2 embryos 
91 TQ Day 3 embryos 161 non-TQ Day 3 embryos 
252 Day 2 embryos 
252 Day 3 embryos 
45 TQ Day 3 SET  43 non-TQ Day 3 SET 
88 Day 3 SETs
164 embryos for further culture
78 blastocysts 
38 TQ blastocyst 40 non-TQ blastocyst 
18 Day 5 SETs
60 cryopreserved  blastocysts
106 single embryo transfers
14 TQ SET  4 non-TQ SET 
86 arrested development b
Fig. 1 Patient selection process and flowchart of oocyte and subsequent
embryo development. COC cumulus–oocyte–complex, MII oocyte
metaphase II oocyte, ICSI intracytoplasmic sperm injection, TQ top
quality, non-TQ non-top quality. aEmbryo grading details are presented
in the BMaterials and methods^ section. bArrested development refers to
embryos that failed to progress from day 3 to the blastocyst stage
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(25.9 ± 9.9 vs. 30.1 ± 14.7 ng/ml, P = 0.016 and 24.56 ± 7.9 vs.
29.59 ± 14.8 ng/ml, P = 0.007, respectively). There was no dif-
ference in FF vitamin D levels between the TQE and non-TQE
blastocyst (25.8 ± 9.0 vs. 26.3 ± 8.6, ng/ml P = 0.39).
Follicular fluid vitamin D level and clinical outcomes
In 106 SETs, 88 embryos were transferred on the third day,
and the remaining 18 were transferred on the fifth day of the
culture (Fig. 1). A positive pregnancy test was detected in 42/
106 (39.6%) of the patients, while clinical pregnancy and live
birth rates in 36/106 (34%) and 34/106 (32.1%), respectively.
As shown in Fig. 3, positive hCG, clinical pregnancy, and live
birth rates were achieved from embryos derived from oocytes
that grew in FF with significantly lower 25(OH)D levels than
in follicles not associated with subsequent pregnancy
(P < 0.001). Specifically, the concentration of 25(OH)D in
FF in women with negative hCG was 32.23 ± 20.21 ng/ml,
positive hCG 23.62 ± 6.09 ng/ml, clinical pregnancy 23.13 ±
6.09 ng/ml, and live birth 23.45 ± 6.11 ng/ml (P < 0.001).
Serum vitamin D level and ICSI outcomes
Table 2 compares outcomes from patients with and without vi-
tamin D deficiency according to the Institute of Medicine (IOM)
and the Endocrine Society clinical practice guidelines [28, 29].
Fig. 2 Vitamin D concentrations
in FF in relation to the outcome of
corresponding oocytes:
fertilization and subsequent early
embryo development. Each bar
represents mean ± SD. FF
follicular fluid, TQE top quality
embryo, non-TQE non-top
quality embryo. Embryo grading
details are provided in the
BMaterials and methods^ section
Fig. 3 Vitamin D levels in FF
corresponding to oocytes that led
to development of transferred
embryos and subsequent clinical
outcomes. Each bar represents
mean ± SD; *P < 0.001 vs.
negative hCG following SET. FF
follicular fluid, SET single
embryo transfer
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Table 2 Embryo development
and clinical outcomes according
to serum vitamin D serum status
Vitamin D
< 20 ng/ml
Vitamin D
≥ 20 ng/ml
P value
Patients’ characteristics
Number of patients 114 84
Age [years], mean (SD) 34.3 (4.1) 34.25 (3.7) 0.810e
Vitamin D status [ng/ml], mean (SD) 14.53 (3.7) 25.08 (4.0) 0.001e
Number of PCOS patients, n (%) 18 (15.8) 9 (10.7) 0.186f
PCOS vitamin D status [ng/ml], mean (SD) 12.32 (3.2) 24.03 (3.3) 0.001e
BMI [kg/m2], mean (SD) 22.89 (3.6) 23.51 (3.9) 0.734e
Number of obese patients, n (%) 26 (22.8) 20 (25) 0.826f
Obese vitamin D status [ng/ml], mean (SD) 14.1 (3.5) 25.6 (5.5) 0.001e
Duration of infertility [years], mean (SD) 3.3 (1.6) 3.5 (1.3) 0.792e
Type of infertility, n (%)a
Primary infertility 93 (81.5) 69 (82.1) 0.444f
Mild male factor 11 (9.6) 9 (10.7) 0.473f
Idiopathic 71 (62.3) 52 (61.9) 0.605f
Ovulatory disorders 15 (13.1) 12 (14.2) 0.251f
Tubal factor 10 (8.7) 8 (9.5) 0.639f
Endometriosis 14 (12.3) 10 (11.9) 0.488f
Previous IVF/ICSI attempts, n (%)
0 86 (75.4) 63 (75) 0.428f
≥ 1 28 (24.6) 21 (25)
Stimulation protocol characteristics
Basal AMH [ng/ml], mean SD 2.84 (1.56) 2.60 (1.98) 0.271e
Basal FSH [mIU/ml], mean SD 6.97 (4.27) 7.83 (4.09) 0.103e
Type of GnRH analog
Antagonist, n (%) 59 (51.7) 48 (57.1) 0.175f
Agonist, n (%) 55 (48.2) 36 (42.9)
Gonadotrophins [IU], mean (SD) 2125 (657) 2242 (1121) 0.694e
Estradiol on the day of hCG [pg/ml], mean (SD) 2493 (1326) 2263 (1394) 0.259e
Progesterone on the day of hCG [ng/ml], mean (SD) 0.93 (0.43) 0.89 (0.36) 0.373e
Embryological outcome
Number of oocytes retrieved, mean (SD) 10.01 (4.9) 8.86 (3.9) 0.075e
Number of MII oocytes, mean (SD) 6.28 (2.7) 6.16 (2.6) 0.752e
Number of MI oocytes, mean (SD) 2.08 (1.9) 1.71 (1.6) 0.152e
Number of GVoocytes, mean (SD) 1.52 (1.9) 1.11 (2.1) 0.163e
Fertilization rate (%), mean (SD) 71 (29) 61.6 (29) 0.026e
Cycles with no available embryo for ET, n (%) 4 (3.5) 4 (4.8) 0.489e
Percentage of top quality embryos (%), mean (SD) 23.8 (22.4) 19.8 (21.2) 0.209e
Single embryo transfera, n (%) 110 (96.5) 80 (95.2) 0.423f
Elective SET (eSET)b, n (%) 57 (51.8) 41 (51.2) 0.683f
Top quality transferred embryo, n (%) 67 (60.9) 43 (53.7) 0.235f
Season of embryo transfer, number of patients (%) 110 80
Winter 5 (4.5) 3 (3.7) 0.073g
Spring 39 (35.5) 20 (25)
Summer 55 (50) 47 (58.8)
Autumn 11 (10) 10 (12.5)
Clinical outcomes
Positive hCG, n (%)c 57 (51.8) 23 (28.7) 0.001f
Clinical pregnancy, n (%) 53 (48.2) 20 (25) 0.001f
Miscarriage, n (%)d 16 (14.5) 3 (3.8) 0.013f
Live birth, n (%)b 41 (37.3) 20 (25) 0.067f
a In eight cases, there was no ET and these patients were not included in the live birth analysis
b Elective single transfer (eSET) represents a transfer of one embryo from a larger cohort of available day 3 or 5
embryos suitable for embryo transfer
c Positive hCG rate after SET, measured 3 weeks after oocyte retrieval
dMiscarriage was defined as any pregnancy loss after the pregnancy was confirmed 3 weeks after retrieval by a
positive beta-hCG. This corresponds to 5 weeks of gestation when the gestational sacs on the US can be
visualized.
e Student’s t test
f Chi-square test
g Fisher’s exact test
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No significant differences were observed between these two
groups concerning age, BMI, duration and type of infertility,
the number of retrieved oocytes, the number of mature MII oo-
cytes, the number of cycles with no available embryo for ET, the
percentage of top quality embryos, or the quality of transferred
embryo and cycles with elective SET (eSET). However, women
with a vitamin D deficiency had a significantly higher fertiliza-
tion rate compared to women with normal vitamin D levels (71
vs. 61.6%, P = 0.026) (Table 2). The incidence of vitamin D
deficiency did not vary significantly across the seasons.
Overall, 42.1% of patients had a positive pregnancy test,
38.4% a clinical pregnancy, and 32.1% had a live birth. When
analyzing the results according to 25(OH)D serum levels, we
found that patients with a vitamin D deficiency had signifi-
cantly higher clinical pregnancy rates compared to those with
25(OH)D values exceeding 20 ng/ml (48.2 vs. 25%, P =
0.001). However, serum vitamin D-deficient patients had also
significantly higher miscarriage rates (14.5 vs. 3.8%, P =
0.013). The difference in the live birth rates between these
groups did not reach statistical significance (37.3 vs. 25%,
P = 0.067). According to ROC, serum vitamin D had high
sensitivity and specificity for miscarriage with a cutoff value
of 16.9 ng/ml and AUC = 0.78, P = 0.001 (Table 3).
Logistic regression analysis identified the following variables
as associated with miscarriage: vitamin D deficiency, number of
retrieved oocytes, and availability of TQEs. Normal vitamin D
serum levels (≥ 20 ng/ml) were associated with lower miscar-
riage rates, with an odds ratio (OR, 95%CI) of 0.88 (0.80–0.97)
(P = 0.01). The predictors of live birth were as follows: age,
vitamin D deficiency, progesterone elevation on the day of
hCG, number of retrieved oocytes, and availability of TQEs.
Notably, womenwith a vitamin D deficiency had slightly higher
live birth rates with an OR (95% CI) of 1.09 (1.04–1.15), (P =
0.01) than women with normal vitamin D levels (Table 4).
Discussion
IVF provides a unique opportunity to study the relationship of
both systemic and intrafollicular levels of vitamin D with the
fate of individual oocytes since it is possible to track follicular
development, oocyte fertilization, embryo development, im-
plantation, and ultimately, clinical outcome. To date, the
relationship between the level of vitamin D and IVF out-
come(s) remains controversial [27, 33, 34]. Available system-
atic reviews and meta-analyses of serum vitamin D and IVF
outcomes do not support the idea of routinely screening
25(OH)D serum status to predict the clinical pregnancy rate,
nor supplementing vitamin D in couples undergoing ART [27,
33, 34]. In this study, 25(OH)D serum deficiency was associ-
ated with a slightly higher odds of life birth despite a higher
miscarriage rate. Hence, it appears that the serum level of vita-
min D has a complex relationship with clinical outcomes.
Furthermore, present findings differ from the conclusions of
several reviews on this subject, whereby preponderance of ev-
idence suggested that a lower serum vitamin D was associated
with lower live birth rates [27, 33, 34]. However, it is important
to note that in the current study, the level of vitamin D was
determined only on the day of oocyte pick-up. Vitamin D sup-
plementation during pregnancy is associated with increased
circulating 25(OH)D levels, birth weight, and birth length [35].
Consistent with our observations, previous studies (using
pooled FFs) have demonstrated a significant correlation of se-
rum and FF levels of 25(OH)D noting also that the mean vita-
min D concentration was higher in FF than serum [13, 15, 18,
23]. These observations indicate that peripheral vitamin D status
is a reliable indicator of 25(OH)D availability within the ovary.
The mechanisms of action by which vitamin D may affect oo-
cyte competence in IVF remain unclear. By evaluating vitamin
D levels in a large number of individual follicles andmonitoring
the outcome of their corresponding oocytes, the present study
demonstrates for the first time that local-intrafollicular vitamin
D levels strongly and negatively correlate with the quality of the
oocyte. Based on these observations, we propose that
intrafollicular concentration of vitamin D may be viewed as a
marker of oocyte quality. Furthermore, one can speculate that
the local and yet not characterized actions of vitamin D may
contribute to oocytes’ ability to be successfully fertilized, devel-
op into an embryo, and ultimately affect the likelihood of preg-
nancy in an infertile population undergoing ICSI/SET. Potential
explanations for these findings may invoke either direct or in-
direct action of vitamin D on pathways involved in the regula-
tion of follicle/oocyte maturation [9, 36, 37].
Previous studies examining 25(OH)D FF levels and IVF
outcomes yielded conflicting results. Ozkan et al. [15] report-
ed a positive association between FF 25(OH)D levels and IVF
Table 3 Receiver operating
characteristic curve for vitamin D
serum status
Cutoff value
(ng/ml)
AUC SE 95% CI z P
Availability of top
quality embryo
12.7 0.56 0.03 0.50 0.62 1.87 0.06
Miscarriage 16.9 0.78 0.03 0.71 0.84 8.53 < 0.01
Live birth 20.3 0.57 0.03 0.50 0.63 2.03 0.04
AUC the area under the ROC curve, SE standard error, 95% CI 95% confidence intervals, z z score
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outcomes, with patients in the highest tertile of FF 25(OH)D
distribution being almost fourfold more likely to achieve a
clinical pregnancy rate (CPR) compared to patients in the
lowest tertile. In contrast, Anifandis et al. observed a negative
relationship between increasing FF vitamin D levels and IVF
outcomes [23]. When comparing the FF pooled from all re-
trieved follicles between patients with a serum vitamin D level
less than 20 ng/ml and to those with 21–30 and > 30 ng/ml, a
significantly higher mean score of embryo quality, higher CPR
per women and higher CPR per ETwas found in patients with a
vitamin D deficiency [23]. Subsequently, Aleyasin et al. dem-
onstrated decreased fertilization rates with increasing tertiles of
25(OH)D level in follicular fluid, showing a potentially nega-
tive association between 25(OH)D and oocyte competence
[18]. However, these data are difficult to interpret because all
of the women in this population, except for one, were vitaminD
deficient [18]. Recently, Firouzabadi et al. divided patients ac-
cording to vitamin D serum levels into three groups: deficient,
insufficient, and sufficient defined as < 10, 10–29, and 30–
100 ng/ml, respectively [13]. In contrast to the reports by
Anifandis et al. and Aleyasin et al., the fertilization rates and
implantation rates were related to vitamin D levels.
Furthermore, good-quality embryos in the serum deficient, in-
sufficient, and sufficient groups were also found at comparable
rates of 82.6, 90.2, and 86.7%, respectively. However, the level
of vitamin D in the FF of the pregnant group was 22.17 ±
17.21 ng/ml compared with 26.14 ± 19.33 ng/ml in the non-
pregnant group. The lack of statistical significance (P = 0.17)
in that study could be related to the sample size, as only 7% of
women were vitamin D sufficient in that studied population.
Our study has several strengths. Its primary strength per-
tains to the study design, whereby we were able to follow the
fate of individual oocytes from fertilization through the assess-
ment of embryo development to implantation and ultimately
to live birth by evaluating patients who underwent a single
embryo transfer. In contrast, previous reports included patients
with an average of two to four transferred embryos [13, 15, 18,
23, 24]. Consequently, in this study, we were able to assess the
direct relationship of FF vitamin D level with the development
of a particular embryo and subsequent pregnancy. Another
strength of the current study is the relatively high number of
participants. Previous reports evaluated 80–101 patients [15,
18, 23, 24], while we prospectively assessed 198 participants.
Furthermore, our population was homogeneous whereby all
subjects were Caucasian. Previously published reports evalu-
ated various populations such as Iranian [13, 18, 24], Greek
[23], and highly diverse American patients including 53%
Caucasian, 20% Asian, 16% Hispanic, and 7% African-
American subjects [15]. The issue of race is relevant since
Rudick et al. demonstrated that race affects the relationship
between vitamin D status and pregnancy rates after IVF [16].
For example among non-Hispanic whites, pregnancy rates
declined with progressively lower levels of vitamin D, while
among Asians, the reverse was observed.
To focus on the evaluation of oocyte competence, we ex-
cluded couples with moderate and severe male factor and
therefore minimized the role of spermatozoa as a factor affect-
ing embryo development. In contrast, in some previous stud-
ies, male factor was present in 58–65% of couples [13, 24]
while in other studies [15, 18, 23], the indications for IVF/
ICSI were not mentioned. Additionally, to test only mature
oocytes, we evaluated only patients undergoing ICSI.
This study has several limitations. First, a further general-
ization of our findings will require testing of women from
populations excluded from the present study. Second, this
study evaluated vitamin D levels from the lead follicle only.
Third limitation pertains to the nature of the observational
study and consequently demonstration of an association but
not causation with regard to the relationship between vitamin
D level and biological outcomes. Demonstration of causation
will require new interventional studies. Lastly, we did not
measure vitamin D binding globulin level (VDBP).
Table 4 Logistic regression
models B
a SE Wald χ2 P value ORa 95% CI
Miscarriage
Vitamin D serum level ≥ 20 ng/ml − 0.12 0.05 6.43 0.01 0.88 0.80–0.97
Number of oocytes retrieved − 0.25 0.09 7.80 0.01 0.77 0.64–0.93
TQEs not available 1.33 0.37 12.67 0.01 3.80 1.81–7.96
Live birth
Age 0.22 0.05 21.93 0.01 1.25 1.14–1.38
Vitamin D serum level < 20 ng/ml 0.09 0.03 10.76 0.01 1.09 1.04–1.15
Number of oocytes retrieved 0.45 0.09 23.89 0.01 1.58 1.31–1.90
TQEs available 1.09 0.20 29.49 0.01 8.89 4.04–19.56
Progesterone elevation on the day of hCG − 0.07 0.03 4.19 0.04 0.93 0.86–0.99
B regression coefficient, SE standard errors of regression coefficient, OR odds ratios, 95% CI 95% confidence
intervals
aB < 0 and OR < 1 mean miscarriage or live birth is inclined to be negative
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Therefore, in our study, we consider a total 25(OH)D level, as
bioavailable 25(OH) D is defined by circulating 25(OH)D not
bound to VDBP, which is analogous to the definition of bio-
available testosterone [38]. In humans, common genetic poly-
morphisms produce three major circulating variants of the
VDBP (Gc1F, Gc2, and Gc1S) [39]. The phenotypic varia-
tions in the VDBP amino acid sequence are distinguished by
single nucleotide polymorphisms (SNPs) rs7041 and rs4588.
In 1993, Constans and Arnaud showed differences between
VDBP polymorphisms, where the affinity of Gc1F was four
times higher than that of Gc2 and double that of Gc1S [40].
Blacks and Asians are more likely to carry Gc1F, which has
the highest affinity for 25(OH)D and is associated with low
VDBP levels. Whites are more apt to carry Gc1S while Gc2,
which has a lower affinity for 25(OH)D and is associated with
higher VDBP levels, is frequently found in whites and rarely
found in blacks. The high prevalence of Gc1F in blacks results
in concentrations of bioavailable 25(OH)D similar to those in
whites [41]. Therefore, bioavailable 25(OH)D may be a more
appropriate cross-racial marker of vitamin D sufficiency [42].
It is worth stressing the fact that since levels of total 25(OH)D
are, in part, genetically determined, our study is based on
Caucasian population only.
Additionally, the issue of VDBP is particularly complicated
because it is a highly polymorphic serum protein with three
common alleles and more than 120 rare variants with different
binding affinities [43]. Thus, standardization of such assays is
currently problematic because the available calibration mate-
rials tend to contain either a single VDBP variant or a mix of
variants of unknown composition [39]. Furthermore, great
strides have been made in recent years to improve the accura-
cy of 25(OH)D assays, since a study done in 2012 used the
same VDBP method adopted in the evaluation [43]. In our
study, we have used up-to-date LIAISON Kit. In automated
assays, 25(OH)D must be liberated from VDBP, and its
rebinding prevented [39]. The assumption is that whatever
approach is used, either 100% of the 25(OH)D is removed
from the VDBP or, if not, the percentage removed is the same
in all samples. In the Caucasian population, the most common
VDBP phenotypes are Gc1S and Gc2 which have the lowest
affinity for 25(OH)D [44].
Finally, recent study from Fabris et al. on oocyte donor pop-
ulation did not show any dependence or statistical association
between the values of total 25(OH)D and bioavailable
25(OH)D with regard to the ovarian reserve, response to ovar-
ian stimulation, oocyte quality in egg donors, or ongoing preg-
nancy rates after fresh embryo transfer in oocyte recipients [19].
Given the prevalence of vitamin D deficiency, which is esti-
mated to affect approximately 1 billion people worldwide [1], the
issue of the clinical impact of 25(OH)D on oocyte development
is of great importance. The relationship between vitamin D and
oocyte quality may be influenced by the bioavailability of vita-
min D within an individual follicle. Recent data from rhesus
monkey follicular cultures by Xu et al. [45] show that
1,25(OH)2D impacts follicular survival and growth, as well as
oocyte growth in a dose- and stage-dependent manner. The low
dose of 1,25(OH)2D promoted preantral follicular survival while
a high dose led to greater follicular diameter. However, larger
follicular size may not necessarily correspond to a higher quality
of the oocyte. In our study, local-follicular fluid 25(OH)D con-
centration was strongly and negatively correlated with the oocyte
quality. To reconcile these discordant observations, further stud-
ies should evaluate how follicular vitamin D may affect oocyte
competence. Such studies may extend present findings and may
provide a mechanistic explanation for the relationship of vitamin
D and clinical outcomes. In the long term, local concentrations of
vitamin D may become relevant to clinical decisions such as the
selection of the best oocytes and therefore help to improve the
results of IVF/ICSI.
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